Search

The Global Vision Database

The overall goal of the Global Vision Database (GVD) [1] is to develop and deploy new and improved evidence on the prevalence of blindness and vision impairment (VI) globally. It is a repository which allows us to assess the causes...

Contemporary glaucoma therapy: spoilt for choice

The goal of glaucoma management is to prevent visual loss and disease progression in the patient’s lifetime through effective lowering of intraocular pressure (IOP), the primary modifiable risk factor in glaucoma. Sustained and consistent IOP reduction is key to halting...

Grading of ocular inflammation in uveitis: an overview

Anterior uveitis is the commonest form of uveitis, which can lead to severe morbidity if not treated appropriately [1]. Data from general ophthalmology practices suggest around 90% of uveitis encountered by comprehensive ophthalmologists is anterior uveitis [2]. Intermediate (vitreous), posterior...

Intravitreal injections delivered by ophthalmic clinical nurse specialists

Intravitreal injections of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab, for the treatment of wet age-related macular degeneration (AMD) was approved by National Institute for Health & Care Excellence (NICE) in 2008 [1]. The Manchester Royal Eye Hospital (MREH),...

Shifting the paradigm of managing patients in medical retina: how real-world data can help us to improve clinical practice

The ophthalmic subspecialty of ‘medical retina’ has undergone dramatic changes in recent years. With the introduction of ranibizumab (Lucentis, Novartis), a specialty formerly dominated by laser-based therapies has been transformed to become, in large part, pharmacotherapy-based. To date, these pharmacotherapies...

Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...

The Ophthalmic Imaging Association holds successful first virtual conference

When the coronavirus pandemic hit, many of the things we enjoy were postponed or cancelled, including the 2020 Ophthalmic Imaging Association (OIA) conference. The Ophthalmic Imaging Association committee began focusing on 2021 but it soon became apparent a face-to-face conference...

Dr William Mackenzie: a founding figure of modern ophthalmology

The author looks at the career of William Mackenzie and the important role he played in establishing the status of ophthalmology as a recognised medical speciality. There are certain individuals who, blessed with ability and means, are destined to leave...

Pituitary tumours: why are they so often missed?

Part 3: Clinical features, assessment and management (see also Part 2, and Part 1) As previously mentioned in this treatise [1] pituitary tumours are common, occur in all age groups and can present with anything from minimal visual symptoms to...

Harry Moss Traquair: Edinburgh Ophthalmologist and Father Figure of Perimetry

It is a unique honour bestowed upon only a few clinicians, that their name becomes for evermore associated with the subject of their particular expertise and knowledge. Such an individual is undoubtedly Harry Moss Traquair, an Edinburgh-based ophthalmologist, who in...